Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Recommendation of "Buy" from Brokerages

Key Points

• Lexeo Therapeutics, Inc. has received a consensus recommendation of "Buy" from six analysts, with an average 12-month price target of $17.17.
• Analysts have varying target prices for the stock, with Oppenheimer setting a target of $20.00 and JPMorgan reducing theirs from $16.00 to $10.00.
• Institutional investors own 60.67% of Lexeo Therapeutics' shares, highlighting strong support from major stakeholders in the company.

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has received a consensus rating of "Buy" from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have covered the stock in the last year is $17.1667.

Several equities research analysts recently weighed in on the stock. Oppenheimer assumed coverage on shares of Lexeo Therapeutics in a research note on Thursday. They set an "outperform" rating and a $20.00 price objective on the stock. HC Wainwright dropped their price objective on shares of Lexeo Therapeutics from $23.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. JPMorgan Chase & Co. dropped their price objective on shares of Lexeo Therapeutics from $16.00 to $10.00 and set an "overweight" rating on the stock in a research note on Friday, May 30th. Finally, Chardan Capital decreased their target price on shares of Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th.

Lexeo Therapeutics Stock Up 3.5%

Shares of Lexeo Therapeutics stock traded up $0.16 during trading on Thursday, reaching $4.77. The company had a trading volume of 241,554 shares, compared to its average volume of 675,770. The company has a market cap of $158.35 million, a price-to-earnings ratio of -1.45 and a beta of 1.35. The firm's fifty day moving average is $3.99 and its 200-day moving average is $3.72. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.42 and a current ratio of 3.42. Lexeo Therapeutics has a fifty-two week low of $1.45 and a fifty-two week high of $12.95.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.19). On average, analysts anticipate that Lexeo Therapeutics will post -3.14 EPS for the current year.

Institutional Trading of Lexeo Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in LXEO. Millennium Management LLC lifted its position in shares of Lexeo Therapeutics by 282.5% in the 4th quarter. Millennium Management LLC now owns 141,951 shares of the company's stock valued at $934,000 after acquiring an additional 104,837 shares in the last quarter. Wellington Management Group LLP grew its stake in Lexeo Therapeutics by 48.3% in the 4th quarter. Wellington Management Group LLP now owns 76,981 shares of the company's stock valued at $507,000 after buying an additional 25,089 shares during the last quarter. Marshall Wace LLP acquired a new position in Lexeo Therapeutics in the 4th quarter valued at $117,000. BNP Paribas Financial Markets grew its position in Lexeo Therapeutics by 523.1% in the 4th quarter. BNP Paribas Financial Markets now owns 34,527 shares of the company's stock worth $227,000 after purchasing an additional 28,986 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in Lexeo Therapeutics by 30.1% in the 4th quarter. JPMorgan Chase & Co. now owns 13,371 shares of the company's stock worth $88,000 after purchasing an additional 3,093 shares during the last quarter. 60.67% of the stock is owned by institutional investors and hedge funds.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.